Sensyne Health and Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH) have signed a strategic research agreement (SRA) for the development of new treatments for childhood illnesses.
Under the five-year non-exclusive agreement, the partners will develop the treatments through the ethical application of clinical artificial intelligence (AI) research on anonymised patient data.
Go deeper with GlobalData
The agreement is aimed at enabling the ethical application of Clinical AI research for improving paediatric clinical outcomes.
Additionally, new research would be carried out into new medicines for identifying better ways to treat childhood diseases that are rare and complex.
Sensyne and GOSH will initially focus on developing a clinical decision support algorithm to help clinicians caring for children with chronic kidney disease.
Further clinical support algorithms for other diseases in children will be developed based on this.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataUnder the agreement, Sensyne and GOSH will focus on paediatric drug discovery, clinical decision support tools to support children’s care and clinical trial design.
Great Ormond Street Hospital chief executive Matthew Shaw said: “Research into developing new diagnosis and treatments is vital and we are always looking to find ways to improve patient outcomes, while making sure their information is safe and secure.
“Children are at the heart of everything we do and this collaboration is no different. It will offer the potential to use digital innovation to find and develop diagnosis and treatments much faster, not just for GOSH patients but children across the country and internationally.”
Through the agreement, Sensyne will get non-exclusive access to longitudinal de-identified and anonymised patient data for evaluation with the help of its expertise in clinical AI.
A patient population of around 320,000 people is covered in the dataset.
GOSH will anonymise the complete data accessed by Sensyne beforehand and the provision of the data will operate under an agreed data processing protocol under GOSH governance oversight.
During the five-year term of the contract, GOSH will receive an investment of £250,000 a year from Sensyne for specific investments in information technology for the curation and analysis of data under the agreement.
Additionally, it will receive a royalty on revenues generated by Sensyne from the research undertaken.
